Mucopolysaccharidosis Type I (MPS I)
Rare Disease·MeSH: Mucopolysaccharidosis I
Prevalence
5.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| RGX-111 | REGENXBIO Inc. (RGNX) |
Frequently asked questions
How many drugs are in development for Mucopolysaccharidosis Type I (MPS I)?
BioSniper tracks 1 drug in development for Mucopolysaccharidosis Type I (MPS I) across 1 company.
How many clinical trials target Mucopolysaccharidosis Type I (MPS I)?
There are 1 clinical trial targeting Mucopolysaccharidosis Type I (MPS I) tracked by BioSniper.
What is the prevalence of Mucopolysaccharidosis Type I (MPS I)?
The estimated prevalence of Mucopolysaccharidosis Type I (MPS I) is approximately 5.0 per 100,000 population.
Deep-dive into Mucopolysaccharidosis Type I (MPS I)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis